Simrat Randhawa sold $2.5M of DNTH
EVP, Head of R&D at Dianthus Therapeutics, Inc. /DE/. 23,124 shares at an average of $106.41, traded Sep 1, 2026, filed Sep 3, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.5M at market
- +20Share of holdings soldSold 85% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001992260-26-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +7,500 | $17.88 | $134k | 11,500 | 40 d ago |
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +6,249 | $21.77 | $136k | 17,749 | 40 d ago |
| Sep 1, 2026 | MOption exercise Common Stock10b5-1 | +9,375 | $22.07 | $207k | 27,124 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2,600 | $105.19 | $273k | 24,524 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -7,215 | $106.25 | $767k | 17,309 | 40 d ago |
| Sep 1, 2026 | SOpen-market sale Common Stock10b5-1 | -13,309 | $106.74 | $1.4M | 4,000 | 40 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 56,776 | 40 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,249 | $0.00 | $0 | 41,676 | 40 d ago |
| Sep 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,375 | $0.00 | $0 | 87,500 | 40 d ago |
Related signals
Other insiders at Dianthus Therapeutics, Inc. /DE/ and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Edward Carr CHIEF ACCOUNTING OFFICER | $2.0M 20,000 shares | -100% | |
| 30Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $327k 2,778 shares | -100% | |
| 29Weak | Dianthus Therapeutics, Inc. /DE/ | Simon Read director | $304k 2,777 shares | -100% | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.2M 20,000 shares | -522% | |
| 38Weak | Dianthus Therapeutics, Inc. /DE/ | Anne McGeorge director | $845k 7,750 shares | -100% | |
| 50Moderate | Dianthus Therapeutics, Inc. /DE/ | Marino Garcia CEO AND PRESIDENT | $18M 166,000 shares | -72% | |
| 32Weak | Dianthus Therapeutics, Inc. /DE/ | Ryan Savitz EVP, CFO & CBO | $3.2M 31,249 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Adam M Veness SVP, General Counsel and Sec. | $2.4M 30,000 shares | -100% | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | Simrat Randhawa EVP, Head of R&D | $2.4M 26,530 shares | -87% | |
| 7Weak | Dianthus Therapeutics, Inc. /DE/ | Paula Soteropoulos director | $51k 599 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.